Media Centre
Latest press releases
-
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer
-
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
-
Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial
-
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
-
9M and Q3 2024 results
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
